Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.42 |
| ▸ | JAK2 | O60674 | 7/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.38 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.35 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163077 | 0.79 | KCNH2 (0.51) | HTR1ADRD3 | |
| SCHEMBL19651934 | 0.78 | ADRB2 (0.41) | HTR6HTR2ACDK2 | |
| SCHEMBL1163715 | 0.77 | LMNA (0.47) | HTR7HTR1AHTR2AHTR2CDRD3 | |
| SCHEMBL19651874 | 0.76 | ADRB2 (0.40) | HTR6HTR2A | |
| SCHEMBL1163045 | 0.71 | ADRB2 (0.43) | HTR2A | |
| SCHEMBL1163108 | 0.70 | ADRB2 (0.45) | HTR2A | |
| SCHEMBL16286333 | 0.70 | HRH3 (0.45) | HTR6HTR1AHTR2AHTR2C | |
| SCHEMBL1163581 | 0.70 | ADRB2 (0.43) | HTR6 | |
| SCHEMBL24642108 | 0.70 | HTR6 (0.61) | HTR6HTR7HTR2AHTR2CAGXT | |
| SCHEMBL30017234 | 0.70 | HTR6 (0.61) | HTR6HTR7HTR2AHTR2CAGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | claimed |
| EP-2464227-A1 | COMPOUNDS AND METHODS OF USE THEREOF | Galenea Corporation (US) | 2012-06-20 | — | — | EP | claimed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | claimed |
| WO-2011019738-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2011-02-17 | — | — | WO | claimed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| EP-2464227-A1 | COMPOUNDS AND METHODS OF USE THEREOF | Galenea Corporation (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| WO-2011019738-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR6 12/4885JAK2 138/4885PTK2 3447/4885 |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR6 12/4885JAK2 138/4885PTK2 3447/4885 |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR6 12/4885JAK2 138/4885PTK2 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.